Short Communication |
Corresponding author: Ivayla Zheleva-Kyuchukova ( iva.jeleva@gmail.com ) Academic editor: Plamen Peikov
© 2023 Ivayla Zheleva-Kyuchukova, Dimitar Kyuchukov.
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Citation:
Zheleva-Kyuchukova I, Kyuchukov D (2023) Amiodarone prevention for atrial fibrillation relapse after surgical ablation. Pharmacia 70(4): 901-904. https://doi.org/10.3897/pharmacia.70.e110256
|
Background: Atrial fibrillation (AF) is the most common heart rhythm disorder. AF ablation based on endovascular or surgical techniques is a standard of care in everyday practice. Early recurrence of atrial arrhythmias is a significant problem after ablative procedures. Prophylactic use of antiarrhythmic drugs has become a possible solution.
Materials and methods: We performed a retrospective observational cohort study of 59 patients with heart disease requiring surgery under extracorporeal circulation (ECC) and have received radiofrequency ablation (RFA) for chronic or persistent AF with a successful conversion to sinus rhythm. Patients were divided into two groups: 36 were treated with amiodarone for three months postoperatively (treatment group), and 23 had no concomitant amiodarone therapy (control group). We compared the groups regarding freedom from recurrent atrial arrhythmia and the frequency of conduction disorders requiring permanent pacemaker implantation.
Results: No differences between the groups were found regarding demographic characteristics, risk profile, and heart diseases indicating cardiac surgery. During follow-up, a significantly higher proportion of patients with sinus rhythm in the group receiving amiodarone was found (80.56% vs. 52.17%; p < 0.041). No cases of premature discontinuation of amiodarone for side effects or noncompliance were registered in the treatment group.
Conclusion: Three months of amiodarone therapy post-surgical RFA of AF is an effective and safe strategy for relapse prevention.
atrial fibrillation, surgical radiofrequency ablation, amiodarone, sinus rhythm
Atrial fibrillation (AF) is the most common heart rhythm disorder (
Amiodarone (class III antiarrhythmic drug) is the most widely used medication in relapse cases. It is indicated for many types of supraventricular and ventricular arrhythmias. It is particularly appropriate for patients with compromised left ventricular function due to the minimal negative inotropic effect and low proarrhythmic effect. Side effects have been shown to increase after prolonged use (above six months), mainly related to the function of the thyroid gland. These facts are the main debate problem on the safety and efficacy of long-term drug therapy (
We carried out a retrospective, observational study of data from 59 consecutive patients with heart disease requiring cardiac surgery under extracorporeal circulation (ECC) and receiving RFA for AF with a successful conversion to sinus rhythm. The preoperative duration of AF was documented by electrocardiography and ranged from 13 to 32 months (mean, 22±10 mo), therefore determined as chronic or persistent. The type of primary heart disease and the corresponding surgical procedures varied. The ablation procedures were performed with a bipolar radio-frequency clamp for making ablation lines using the lesion set described by Cox for the maze intervention (
Comparing the preoperative patient characteristics (Table
Indicators | Control group n = 23 | Treatment group n = 36 | р |
---|---|---|---|
Age, years (mean ± SD) | 60.4 ± 5.21 | 60.7 ±.4.69 | 0.876 |
Female, n (%) | 6 (26%) | 10 (28%) | 0.941 |
EF, % (mean ± SD) | 52.2 ± 12.4 | 51.1 ± 9.8 | 0.713 |
Arterial Hypertension, n (%) | 20 (87%) | 31 (86.1%) | 0.687 |
Diabetes, n (%) | 8 (34.7%) | 13 (36.1%) | 0.698 |
CKD, n (%) | 2 (8.7%) | 3 (8.3%) | 0.255 |
Mean AF duration, months | 21(16–32) | 24(13–28) | 0.553 |
Long-standing AF, n (%) | 12 (52.2%) | 20 (55.5%) | 0.280 |
Mitral stenosis, n (%) | 6 (26%) | 11 (30.5%) | 0.368 |
Mitral regurgitation, n (%) | 5 (21.5%) | 9 (25%) | 0.661 |
Aortic stenosis, n (%) | 4 (17.4%) | 5 (13.9%) | 0.781 |
Aortic regurgitation, n (%) | 3 (13.6%) | 4 (11.1%) | 0.589 |
Coronary artery disease, n (%) | 5 (21.5%) | 7 (19.5%) | 0.687 |
Left atrium size, mm (mean ± SD) | 54 ± 8.9 | 56 ± 4.3 | 0.724 |
EuroSCORE II (mean ± SD) | 2.38 ± 0.33 | 2.55 ± 0.23 | 0.232 |
Both groups had similar surgical outcomes, presented in Table
Indicators | Control group n = 23 | Treatment group n = 36 | р |
---|---|---|---|
Mechanical ventilation > 24 hours, n (%) | 1 (4.35%) | 1 (2.78%) | 0.822 |
Revisions for bleeding, n (%) | 1 (4.35%) | 2 (5.56%) | 0.854 |
Acute renal failure, n (%) | 1 (4.35%) | 2 (5.56%) | 0.554 |
Postoperative PM, n (%) | 3 (13.04%) | 3 (8.33%) | 0.656 |
Hospital stay, days (mean ± SD) | 6.8 ± 0.83 | 6.7 ± 0.68 | 0.899 |
Mortality, n | 0 | 0 | NS |
Stroke/TIA, n | 0 | 0 | NS |
Electrocardioversion, n (%) | 3 (13.04%) | 6 (16.67%) | 0.762 |
No cases of premature discontinuation of amiodarone for side effects or noncompliance were registered in the treatment group. At the 3-rd month, we found a significantly higher proportion of patients with stable sinus rhythm in the group receiving amiodarone compared to the control group (29/36 (80.56%) vs. 12/23 (52.17%); p < 0.041) (Fig.
In this study, we concluded that prophylaxis with amiodarone after surgical RFA is safe and effective, and the result is comparable to the efficacy of this prophylaxis after catheter ablation (
Several studies report a proportional relationship between the rates of early AF relapses (within the third month) and late (after the sixth month) recovery of persistent arrhythmia. However, the general opinion is that a single early arrhythmia recurrence in the first three post-procedure months or the so-called “stabilization period” or “blanking period“ does not mean a particular failure of the ablation procedure. It is before settling on the final rhythm resulting from the ablation procedure. (
The study has many limitations, the most important of which are retrospective patient registration, small total number of patients, and lack of a specific definition according to which the choice was made to continue prophylaxis with amiodarone in some patients or discontinuation in others. In general, in most patients operated on in the earlier years of the study period, amiodarone was discontinued immediately after discharge due to a lack of data on the effectiveness of this prophylaxis in the literature. Another essential problem is the lack of longer-term follow-up for recurrent arrhythmias. Contributing to this is the fact that the use of devices, such as continuous telemetry or longer-term Holter monitoring, is not possible in the current conditions of the healthcare system, where funds for such devices are not provided. However, the tendency of recurrences to become more frequent without treatment and eventually to degenerate again into chronic AF gives us reason to say that many of these cases would be registered at the follow-up examination. Despite the mentioned limitations, the significant difference between the groups allows us to say that the results are representative, especially if they are considered in similar publications. However, in order to strongly recommend the use of prophylaxis with amiodarone after surgical RFA in all patients, larger and randomized trials will be needed.
Short-term prophylactic amiodarone treatment reduces early atrial arrhythmia recurrence after surgical RFA. The biggest concern with long-term treatment with amiodarone remains the manifestation of its side effects, especially regarding thyroid function. However, the course’s relatively short period with careful patient monitoring is safe. Based on this study, we can recommend prophylaxis with amiodarone after surgical RFA for at least three months as an effective and safe strategy.